You are not connected. The newsletter may include some user information, so they may not be displayed correctly.

AMS Newsletter | 29 November 2023

AMS Newsletter | 29 November 2023
AMS
www.menopause.org.au 29 Nov 2023
---
AMS Newsletter
---
Welcome to the AMS Newsletter for doctors and other healthcare professionals who have a special interest in women's health. The content covers information and resources relevant to menopause, midlife and the promotion of healthy ageing.
 

In this edition

{tableofcontents|type:h3}
 

November 2023

Senate Inquiry into issues relating to menopause and perimenopause

You may be aware that on 6 November 2023, the Senate referred the above matter to the Senate Community Affairs References Committee for inquiry and report by 10 September 2024. The terms of reference are available online and are outlined below:

Issues related to menopause and perimenopause, with particular reference to:

  1. the economic consequences of menopause and perimenopause, including but not limited to, reduced workforce participation, productivity and retirement planning;
  2. the physical health impacts, including menopausal and perimenopausal symptoms, associated medical conditions such as menorrhagia, and access to healthcare services;
  3. the mental and emotional well-being of individuals experiencing menopause and perimenopause, considering issues like mental health, self-esteem, and social support;
  4. the impact of menopause and perimenopause on caregiving responsibilities, family dynamics, and relationships;
  5. the cultural and societal factors influencing perceptions and attitudes toward menopause and perimenopause, including specifically considering culturally and linguistically diverse communities and women’s business in First Nations communities;
  6. the level of awareness amongst medical professionals and patients of the symptoms of menopause and perimenopause and the treatments, including the affordability and availability of treatments;
  7. the level of awareness amongst employers and workers of the symptoms of menopause and perimenopause, and the awareness, availability and usage of workplace supports;
  8. existing Commonwealth, state and territory government policies, programs, and healthcare initiatives addressing menopause and perimenopause;
  9. how other jurisdictions support individuals experiencing menopause and perimenopause from a health and workplace policy perspective; and any other related matter.

The AMS Board plans to provide a submission on behalf of AMS members.

Submissions can be made here and are due by 16 February 2024.

Menopausal Hormone Therapy (MHT) Patch discontinuation and shortages

Australia

All doses of Climara are being deleted from the market and there will be a reduction in supply until supply is exhausted.

Product

Composition

Date of deletion

Climara 25

25mcg oestradiol transdermal patch

31 Dec 2023

Climara 50

50mcg oestradiol transdermal patch

15 Mar 2024

Climara 75

75mcg oestradiol transdermal patch

15 Nov 2024

Climara 100       

100mcg oestradiol transdermal patch

30 Sep 2023

There are also a number of MHTs that are currently unavailable.

Product

Composition

Expected supply due

Estalis sequi 50/250

50mcg oestradiol/250mcg norethisterone

15 Dec 2024

Estradot 25

25mcg oestradiol

3 Nov 2023

Estradot 37.5

37.5mcg oestradiol

19 Jan 2024

Estraderm 25

25mcg oestradiol

15 Dec 2023

Estraderm 75

75mcg oestradiol

15 Mar 2024

There is now supply of:

  • Estradot 75 and 100
  • Estraderm 50 and 100
  • Estalis Conti 50/140

The AMS Guide to MHT Doses (Australia only) provides a guideline to approximately equivalent doses of the different MHT/HRT products in Australia.

New Zealand

In New Zealand, there is no stock of Estradot 25 or Estradiol TDP Mylan 25mcg. There is stock of both Estradot 50 and Estradiol TDP Mylan 50mcg. There is stock of Estradot 75 but none of Estradiol TDP Mylan 75mcg. Both Estradot 100 and Estradiol TDP Mylan 100mcg are available. https://pharmac.govt.nz/medicine-funding-and-supply/medicine-notices/oestradiol/?mType=all

The AMS Guide to MHT Doses (New Zealand only) provides a guideline to approximately equivalent doses of the different MHT/HRT products in New Zealand. 

AMS is pleased to present an updated version of the Tibolone as menopausal hormone therapy with thanks to Dr Ashley Makepeace. Tibolone is a synthetic steroid hormone. Its metabolites have oestrogenic, progestogenic and androgenic properties. Indications are for the management of oestrogen deficiency symptoms and for the prevention of bone loss at the time of menopause.

Dr Christina Jang
Coordinator, AMS Information and Fact Sheets

IMS World Congress on Menopause in Melbourne 2024

IMS World Congress on Menopause in Melbourne 2024

Health Professionals - join AMS for Members-only content 

IMS Live 21 November 2023: During the postmenopausal stage women often display adverse lipid profiles; however, evidence is insufficient regarding the association between lipids and reproductive aging in Korean women. Bearing this in mind, Park et al. [1] aimed to characterize lipid changes in relation to the timing of menopause in 1,436 Korean mid-aged (premenopausal) women who had a natural menopause during the follow-up period (median = 15.76 years) from the Korean Genome and Epidemiology Study (KoGES) Ansan and Anseong cohort. Lipid levels were measured every 2 years, and the magnitudes of annual lipid changes and differences in the changes by premenopausal body mass index were estimated using piecewise linear mixed-effects models...

Sexual Health During and After Cancer - video
Dr Bober discusses changes in sexual health during and after cancer. She reviews that sexual recovery after cancer is a process and an important part of a patient’s quality of life. She encourages healthcare professionals to discuss sexual concerns with their patients and direct them to the best resources available.

Brain Teasers: Challenges in the cranium - webinar archive
Moderator: Professor Pauline Maki |Speakers: Professor Anne MacGregor: ‘Menopause and Migraine’ | Doctor Riley Bove: ‘Hormone Therapy and Multiple Sclerosis: Help or hindrance?’

IMS Newsletter November 2023
AMS is an affiliate of IMS See latest available copy.

European Menopause and Andropause Society (EMAS) Newsletter
AMS is an affiliate of EMAS. See a copy of the November newsletter.


---
Australasian Menopause Society
---
Copyright © 2023

Australasian Menopause Society Ltd.

PO Box 280, Healesville, VIC 3777

Tel: +61 3 5962 6241 | Email: ams@menopause.org.au

FacebookLinkedInTwitterInstagram

Health Professionals join the AMS now

Contact us | Unsubscribe
---------

Email built with AcyMailing